Study to Evaluate Safety and Effectiveness of Lenalidomide in Combination With Docetaxel and Prednisone for Patients With Castrate-Resistant Prostate Cancer

• Status: Completed
• Trial end date: 2016-11-28

Summary

The purpose of the study is to determine whether lenalidomide is safe and effective for use in combination with docetaxel and prednisone for the treatment of subjects with metastatic Castrate-Resistant Prostate Cancer.

The addition of lenalidomide to docetaxel and prednisone is proposed to increase the life expectancy of these subjects.

• Phase: Phase 3

Details

• Lead Sponsor: Celgene; Celgene Corporation
• Treatments: Docetaxel; Lenalidomide; Prednisone; Thalidomide